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a  b s  t r a  c t
Objective: To analyse the use, indications and potential risks of tricyclic antidepressants
(TCAs), using a  technological system of clinical alerts at the time of prescription.
Methods: Observational, descriptive, retrospective study on a population covered by  a Colom-
bian  health insurance plan with an average of 2,333,582 members/month. The information
was generated in the PBM (Pharmacy Benefit Management) MC21 Colombia technological
platform.
Results: Of the total members, 368,298 (16%) patients/month on average were  prescribed
medicines; 3,640  (1%) were prescribed TCAs: 2,573 amitriptyline (70%) and 1.062 imipramine
(29%); 817 (22.5%) were over 65 years of age. The median daily dose of amitriptyline and
imipramine  was 25 mg. A  total of 17,153 alerts were reported: 8,685 (51%) for drug-drug
interactions, 7,354 (43%) for drug-age interactions and 543 (3%) for duplicate therapy.
Conclusions: Risks were identified in the prescription of tricyclic antidepressants, especially
in  the over-65 population, where these drugs are used in particular for the management of
neuropathic pain. The clinical alert system at the time of medicinal product formulation can
make an important contribution to the  prevention of potential adverse events associated
with  the use of medicinal products.
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